IRIX Iridex Corp.

Iridex to Participate in Fireside Chat with Stifel Equity Research

Iridex to Participate in Fireside Chat with Stifel Equity Research

MOUNTAIN VIEW, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in a fireside chat with its covering equity research analyst from Stifel.

Management is scheduled to discuss the business on Thursday, December 8, 2022 at 9:00 a.m. PT / 12:00 p.m. ET. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: .

About Iridex

Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit .

Investor Relations Contact:

Philip Taylor

(415) 937-5406



EN
06/12/2022

Underlying

IRIXIridex Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Iridex Corp.

 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Announces New Partnership with EyeProGPO to Expand Member Acces...

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a new partnership with EyeProGPO, an ophthalmology-focused group purchasing organization serving ophthalmology practices, ambulatory surgery centers (ASC), and hospitals across the United States. Through this partners...

April 7, 2026 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial Highlights Generated total revenue ...

March 26, 2026 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex to Report Fourth Quarter and Full Year 2025 Financial Results o...

Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026 MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026. The Company’s management team will host a corresponding conference call...

March 12, 2026 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Announces Plans to Relocate Headquarters

Iridex Announces Plans to Relocate Headquarters Move expected to generate significant cost savings MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company’s headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent for a new lease (the “Lease”). The...

February 2, 2026 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Announces Preliminary Operational and Financial Results for Fou...

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 Demonstrating continued revenue growth, operational efficiencies and positive cash flow MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourt...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch